1.76

3.83% -0.07

After Hours: 1.79 0.03 +1.70%

Bone Biologics Corp (BBLG)

Overview News Price History Financials Why BBLG Down? Discussions Forecast Stock Split

Bone Biologics Corp stock is currently priced at $1.76, with a 24-hour trading volume of 33,011. It has seen a -3.83% decreased in the last 24 hours and a +1.73% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.83 pivot point. If it approaches the $1.76 support level, significant changes may occur.

Previous Close:

$1.83

Open:

$1.83

24h Volume:

33,011

Market Cap:

$1.55M

Revenue:

Net Income/Loss:

$-8.95M

P/E Ratio:

-0.1915

EPS:

-9.19

Net Cash Flow:

$-9.56M

1W Performance:

+12.71%

1M Performance:

+1.73%

6M Performance:

+232.08%

1Y Performance:

+823.88%

1D Range:

$1.70

$1.8307

52W Range:

$0.14

$10.56

Bone Biologics Corp Stock (BBLG) Company Profile

Name

Bone Biologics Corp

Sector

Healthcare (1216)

Industry

Medical Devices (160)

Phone

781 552 4452

Address

2 Burlington Woods Drive, Suite 100, Burlington

Employee

Twitter

Next Earnings Date

2024-05-08

Latest SEC Filings

BBLG's Discussions on Twitter

Bone Biologics Corp Stock (BBLG) Latest News

Why BioVie Shares Are Trading Lower By Around 42%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Why Fisker Shares Are Trading Higher By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Why Titan Pharmaceuticals Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

Benzinga

Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

S&P 500 Edges Higher; Buckle Shares Surge After Q3 Earnings

Benzinga

Bone Biologics Corp Stock (BBLG) Financials Data

Bone Biologics Corp (BBLG) Net Income 2024

BBLG net income (TTM) was -$8.95 million for the quarter ending December 31, 2023, a -502.77% decrease year-over-year.

Bone Biologics Corp (BBLG) Cash Flow 2024

BBLG recorded a free cash flow (TTM) of -$9.56 million for the quarter ending December 31, 2023, a -167.90% decrease year-over-year.

Bone Biologics Corp (BBLG) Earnings per Share 2024

BBLG earnings per share (TTM) was -$76.50 for the quarter ending December 31, 2023, a -139.44% decline year-over-year.

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.